Comparison of colonic transit time between patients with constipation-predominant irritable bowel syndrome and functional constipation

被引:11
|
作者
Ansari R. [1 ]
Sohrabi S. [1 ]
Ghanaie O. [1 ]
Amjadi H. [1 ]
Merat S. [1 ]
Vahedi H. [1 ]
Khatibian M. [1 ]
机构
[1] Digestive, Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, 14117 Tehran, North Kargar Avenue
关键词
Bowel motility; Functional bowel disease;
D O I
10.1007/s12664-010-0015-2
中图分类号
学科分类号
摘要
Background/Aim Functional constipation (FC) and consti-pation-predominant IBS (C-IBS) are two main subtypes of constipation. Using radio-opaque markers is an easy and cost effective method to measure colonic transit time (CTT). We designed this study to compare the CTT between these two groups of constipated patients. Methods Patients with chronic constipation of no organic etiology were classified as having FC or C-IBS according to the Rome II criteria. All patients ingested 10 radio opaque markers daily for six days. A plain abdominal X-ray was taken on the seventh day. To calculate the total and segmental colonic transit time in hours, number of markers in right and left colonic and rectosigmoid area were counted and multiplied by 2.4. The mean total and segmental colonic transit time were compared between the two groups. Results A total of 100 patients (50 FC and 50 C-IBS) were enrolled. The mean (SD) total CTT was not significantly different between FC patients (52.2 [35.5] h) and C-IBS patients (41.2 [31.6] h; p = 0.10). The mean rectosigmoid transit time was significantly slower in FC patients (19.9 [15.5] h) com-pared to C-IBS patients (11.9 [10.6] h; p = 0.003). Conclusion Rectosigmoid transit time in FC patients is slower than in C-IBS patients.
引用
收藏
页码:66 / 68
页数:2
相关论文
共 50 条
  • [1] Abnormal colonic propagated activity in patients with slow transit constipation and constipation-predominant irritable bowel syndrome
    Bassotti, G
    Chistolini, F
    Marinozzi, G
    Morelli, A
    [J]. DIGESTION, 2003, 68 (04) : 178 - 183
  • [2] Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome
    Harish, Kareem
    Hazeena, Kizhekkan
    Thomas, Varghese
    Kumar, Sunil
    Jose, Tony
    Narayanan, Puthiyaveetil
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (08) : 1183 - 1189
  • [3] Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome
    Camilleri, Michael
    McKinzie, Sanna
    Fox, Jean
    Foxx-Orenstein, Amy
    Burton, Duane
    Thomforde, George
    Baxter, Kari
    Zinsmeister, Alan R.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (10) : 895 - 904
  • [4] Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation (FC) or constipation-predominant irritable bowel syndrome (C-IBS).
    Camilleri, M
    McKinzie, S
    Burton, D
    Thomforde, GM
    Zinsmeister, AR
    Bouras, EP
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A845 - A845
  • [5] Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
    Prather, CM
    Camilleri, M
    Zinsmeister, AR
    McKinzie, S
    Thomforde, G
    [J]. GASTROENTEROLOGY, 2000, 118 (03) : 463 - 468
  • [6] Clinical and anorectal manometry profile of patients with functional constipation and constipation-predominant irritable bowel syndrome
    Goyal, Omesh
    Bansal, Monika
    Sood, Ajit
    [J]. INDIAN JOURNAL OF GASTROENTEROLOGY, 2019, 38 (03) : 211 - 219
  • [7] Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation
    Abrahamsson, Hasse
    Ostlund-Lindqvist, Ann-Margret
    Nilsson, Ralf
    Simren, Magnus
    Gillberg, Per-Goran
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2008, 43 (12) : 1483 - 1488
  • [8] Clinical and anorectal manometry profile of patients with functional constipation and constipation-predominant irritable bowel syndrome
    Omesh Goyal
    Monika Bansal
    Ajit Sood
    [J]. Indian Journal of Gastroenterology, 2019, 38 : 211 - 219
  • [9] Tenapanor for constipation-predominant irritable bowel syndrome
    Siddiqui, S.
    Cash, B. D.
    [J]. DRUGS OF TODAY, 2020, 56 (03) : 203 - 210
  • [10] LubiprostoneIn Constipation-Predominant Irritable Bowel Syndrome
    Natalie J. Carter
    Lesley J. Scott
    [J]. Drugs, 2009, 69 : 1229 - 1237